Firefly Neuroscience fell 49.3% from $1.58 to $0.80, behind the S&P 500's +8.0%. Its worst day was Mar 20 (−29.8%), and its low came Feb 23 at $0.64.
Story events cover the past 12 months · Times ET
Nov 19, 2025 – Nov 19, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Firefly Neuroscience closed at its lowest level of the year, 59.6% below where the year started.
−8.2% · S&P 500 −1.0%
- Company reports 20-fold expansion of commercial footprint, 33-fold increase in EEG/ERP brain scan volumes - - Harnessing increased data and cutting-edge supercomputing potentially unlocks new AI-driven biomarker
+126.3%, the year's best day, on 319M shares, the year's heaviest volume · S&P 500 +0.7%
Entry into a Material Definitive Agreement.
+58.0% · S&P 500 −0.6%
EPS of $-0.15 was reported on $412,000.00 revenue.
−0.9% · S&P 500 +2.9%
EPS of $-0.13 was reported on $485,000.00 revenue.
0.0% · S&P 500 +0.6%
EPS of $-0.10 was reported on $514,000.00 revenue.
−4.2% · S&P 500 −0.3%
– This integration of Firefly’s FDA 510(k)-cleared, AI-powered EEG/ERP technology follows Radial’s August 2026 acquisition of the management services organization supporting Mindful Health Solutions, forming the
+37.6% · S&P 500 +0.9%
Collaboration to use Firefly’s growing nationwide network of Evoke™ clinician customers.
+68.9% · S&P 500 +0.5%
EPS of $-0.07 was reported on $647,000.00 revenue.
+4.2% · S&P 500 +2.4%
Where it ended: a close of $0.80 on Nov 19, 2026.
Nothing in the past 12 months.
All AIFF analyst actionsNothing in the past 12 months.
All AIFF dividend history